Desentum received clinical trial approval from Health Canada

The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a clinical study on DM-101PX, an investigational preparation intended for immunotherapeutic treatment of birch pollen allergy. The planned study...

Clinical study with birch pollen hypoallergen DM-101 continues

First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt. In early 2020, Desentum initiated a clinical study to evaluate the safety and tolerability of DM-101, a hypoallergen designed for...

Desentum in the media

Here you can find links to articles about Desentum in international media. To see articles in Finnish media, change the language to Finnish from the upper right corner.

This Hypoallergenic Vaccine Could Alleviate Hay Fever Faster Than Approved Vaccines

Desentum selected for EUR 1.9 million EU grant

Biopharmaceutical company Desentum wins EU grant

Finnish Scientists Discover Vaccine to Eliminate Allergies